Contrast Media & Molecular Imaging

Advancements in Radiomics in Clinical Imaging


Publishing date
01 Mar 2021
Status
Published
Submission deadline
06 Nov 2020

Lead Editor

1Sichuan University, Chengdu, China

2Universitätsklinikum Erlangen, Erlangen, Germany

3Imperial College London, London, UK

4The University of Texas MD Anderson Cancer Center, Houston, USA

5Rutgers University, Piscataway, USA


Advancements in Radiomics in Clinical Imaging

Description

Radiomics, the high-throughput mining of quantitative image features from standard-of-care medical imaging that enables data to be extracted and applied to modern medicine to improve diagnostic, prognostic, and predictive accuracy, is gaining importance in clinical imaging.

To improve the precision of diagnosis and treatment and facilitate the process of detection and analysis, researchers have been committed to the study of clinical imaging. Nowadays, the rapid development of radiomics and validation of medical imaging data that uses image-based signatures for precision diagnosis and treatment provide a powerful tool in modern medicine.

This Special Issue aims to provide a forum to update and discuss new discoveries, challenges, opportunities in the field of radiomics in clinical imaging. Both original research and review articles are welcomed, and studies should focus on major trends and challenges in this field.

Potential topics include but are not limited to the following:

  • The development process of radiomics
  • Radiomics applied to clinical decision making
  • Imaging diagnosis or prognosis of diseases
  • Medical image reconstruction
  • Cellular image analysis
Contrast Media & Molecular Imaging
Publishing Collaboration
More info
Wiley Hindawi logo
 Journal metrics

Metrics will be available once more articles are published.

 Submit Evaluate your manuscript with the free Manuscript Language Checker

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.